WO2021246757A1 - Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 - Google Patents
Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 Download PDFInfo
- Publication number
- WO2021246757A1 WO2021246757A1 PCT/KR2021/006809 KR2021006809W WO2021246757A1 WO 2021246757 A1 WO2021246757 A1 WO 2021246757A1 KR 2021006809 W KR2021006809 W KR 2021006809W WO 2021246757 A1 WO2021246757 A1 WO 2021246757A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- pharmaceutical composition
- radiation therapy
- amino acid
- seq
- Prior art date
Links
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 55
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 46
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 46
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 title description 13
- 108090000623 proteins and genes Proteins 0.000 title description 13
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 155
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 155
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 129
- 201000011510 cancer Diseases 0.000 claims abstract description 81
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims abstract description 53
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 88
- 150000001413 amino acids Chemical class 0.000 claims description 86
- 230000005855 radiation Effects 0.000 claims description 74
- 238000011282 treatment Methods 0.000 claims description 37
- 108700004922 F42A Proteins 0.000 claims description 29
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims description 29
- 102220596838 Non-structural maintenance of chromosomes element 1 homolog_R38A_mutation Human genes 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 26
- 230000001737 promoting effect Effects 0.000 claims description 22
- 102220505697 Palmitoyl-protein thioesterase 1_Y45F_mutation Human genes 0.000 claims description 19
- 102220610852 Thialysine N-epsilon-acetyltransferase_L72G_mutation Human genes 0.000 claims description 19
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 239000000539 dimer Substances 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 9
- 230000001678 irradiating effect Effects 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 32
- 239000000203 mixture Substances 0.000 abstract description 11
- 239000013636 protein dimer Substances 0.000 abstract description 10
- 235000001014 amino acid Nutrition 0.000 description 98
- 229940024606 amino acid Drugs 0.000 description 84
- 230000005764 inhibitory process Effects 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 26
- 230000004614 tumor growth Effects 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 230000001093 anti-cancer Effects 0.000 description 13
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000009395 breeding Methods 0.000 description 9
- 230000001488 breeding effect Effects 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 239000007928 intraperitoneal injection Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000009697 arginine Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 235000008729 phenylalanine Nutrition 0.000 description 5
- 229960005190 phenylalanine Drugs 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 229960001292 cabozantinib Drugs 0.000 description 4
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229940122255 Microtubule inhibitor Drugs 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 229960003005 axitinib Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229960000439 eribulin mesylate Drugs 0.000 description 2
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- -1 iomustine Chemical compound 0.000 description 2
- 229960003784 lenvatinib Drugs 0.000 description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000011375 palliative radiation therapy Methods 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 229960004836 regorafenib Drugs 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000007761 synergistic anti-cancer Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229950009579 axicabtagene ciloleucel Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000054189 human CD80 Human genes 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical group ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 238000002673 radiosurgery Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229950008461 talimogene laherparepvec Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229950007137 tisagenlecleucel Drugs 0.000 description 1
- 108010078373 tisagenlecleucel Proteins 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960001183 venetoclax Drugs 0.000 description 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Definitions
- the present invention relates to a pharmaceutical composition for enhancing radiation therapy comprising a fusion protein comprising an IL-2 protein and a CD80 protein, and a radiation therapy method for cancer using the same.
- Cancer treatment can be largely divided into surgery, radiation therapy, and chemotherapy.
- the number of cancer patients receiving radiation therapy in Korea is increasing every year, and accordingly, the importance of radiation therapy in cancer treatment is also increasing.
- Radiation therapy is currently known as an essential treatment method for various types of cancer.
- the acquisition of radiation resistance of cancer cells and damage to normal tissues during high-dose radiation therapy have been pointed out as problems that reduce the efficiency of radiation therapy. Therefore, research on radiation therapy sensitizers and radiation sensitizing compounds to improve the efficiency of radiation therapy has been attempted ( Oncogene , 23(8): 1599-1607, 2004).
- radiation therapy sensitizers reported so far are mainly anticancer drugs, for example, Taxol and cisplatin, etc. have been reported.
- the toxicity of the anticancer agent is a complex of side effects that appear during radiation therapy, that is, inflammation of the radiation treatment site, gastrointestinal disorder, nausea, vomiting, diarrhea, etc. It has the disadvantage of being limited in its use because it can appear.
- the present inventors studied to develop a radiation therapy enhancer that can be used together with radiation therapy without side effects while having the effect of enhancing radiation therapy for cancer.
- the present invention was completed by confirming that when a fusion protein dimer containing IL-2 protein and CD80 protein in one molecule was treated in combination with radiation, it showed a synergistic effect in cancer treatment.
- one aspect of the present invention provides a pharmaceutical composition for promoting radiation therapy for cancer, comprising a dimer of a fusion protein comprising an IL-2 protein and a CD80 protein.
- Another aspect of the present invention comprises the steps of: irradiating radiation to a cancer site of a mammal other than a human suffering from cancer; and administering the pharmaceutical composition to the mammal.
- composition comprising the dimer of the fusion protein comprising the IL-2 protein and the CD80 protein according to the present invention may be used in combination with radiation therapy to enhance the effect of radiation therapy. Therefore, it is possible to improve the radiation treatment efficiency even for cancer resistant to radiation.
- the fusion protein dimer additionally including the IL-2 protein and the CD80 protein amplifies the activity of systemic immune cells, the anticancer effect of radiation therapy can be enhanced by the fusion protein dimer.
- composition comprising the dimer of the fusion protein comprising the IL-2 protein and the CD80 protein according to the present invention can be used as an adjuvant for radiation therapy to be commercialized in the direction of combination therapy.
- the anti-cancer effect is excellent even at the site not irradiated with radiation when the pharmaceutical composition of the present invention is administered with radiation irradiation, commercial utility is expected to be high.
- 1A to 1C show mGI-101 and/or radiation of the present invention to a tumor-formed mouse after transplantation of the melanoma cell line B16F10, and the anticancer effect at the irradiated tumor site and the non-irradiated site It is a view showing the confirmation of the abscopal effect (abscopal) that the therapeutic effect appears.
- the tumor-formed mouse was irradiated with mGI-101 and/or radiation of the present invention, and (a) the volume of the irradiated right tumor measured using a caliper, (b) the non-irradiated left tumor It is a graph showing the volume of and (c) the average volume of both tumors.
- 2A to 2E are views showing the cancer-forming mice by irradiating mGI-101 and/or radiation of the present invention and confirming the anticancer effect in the irradiated tumor site. Specifically, it shows the tumor growth for each mouse individual when the radiation-irradiated right tumor is irradiated with mGI-101 and/or radiation of the present invention.
- 3A to 3E are views showing the abscopal effect in which a tumor-formed mouse is irradiated with mGI-101 and/or radiation of the present invention and a therapeutic effect is shown in a remote site that is not irradiated with radiation. . Specifically, it shows the tumor growth for each mouse individual when the mGI-101 and/or radiation of the present invention is irradiated to the left tumor not irradiated with radiation.
- 4A to 4C are graphs showing the tumor growth inhibition rate by irradiation with mGI-101 and/or radiation of the present invention. Specifically, (a) a graph showing the tumor growth inhibition rate for the right tumor irradiated with radiation, (b) the tumor growth inhibition rate for the left non-irradiated tumor, and (c) the tumor growth inhibition rate for the average of both tumors.
- One aspect of the present invention provides a pharmaceutical composition for enhancing radiation therapy for cancer comprising a dimer of a fusion protein comprising an IL-2 protein and a CD80 protein.
- an anticancer adjuvant comprising the fusion protein dimer as an active ingredient.
- cancer is classified as a disease in which normal tissue cells proliferate unrestrictedly for some reason and continue to develop rapidly regardless of the living phenomenon of the living body or the surrounding tissue state
- cancer in the present invention is Various cancers of the human body, such as stomach cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer and It may be any one cancer selected from the group consisting of lymphoma, but is not limited to the above type. In addition, for the purpose of the present invention, it may be a cancer that is resistant to radiation, but is not limited thereto.
- the term “radiation therapy enhancement” refers to enhancing the sensitivity of cells to radiation in the treatment of diseases using radiation, thereby ultimately enhancing the therapeutic effect on diseases.
- the radiation sensitivity of cancer cells is enhanced, thereby making it possible to produce a killing effect and an inhibitory effect on the proliferation of cancer cells.
- Radiation therapy for the cancer includes a variety of known radiotherapy (radiotherapy), for example, X-ray deep treatment, radium therapy, cobalt 60 mass irradiation, ultra-high pressure radiation therapy and radioactive isotope internal therapy, etc.
- radiotherapy for example, X-ray deep treatment, radium therapy, cobalt 60 mass irradiation, ultra-high pressure radiation therapy and radioactive isotope internal therapy, etc.
- the present invention is not limited thereto.
- the fusion protein dimer comprising the IL-2 protein and the CD80 protein of the present invention was treated in combination with radiation therapy to a mouse having a tumor after transplantation of the melanoma cell line B16F10.
- the fusion protein By more effectively reducing the growth of this tumor, it was confirmed that it can be used as a combination or adjuvant for anticancer treatment ( FIGS. 1A to 4C ).
- the pharmaceutical composition for enhancing radiation therapy comprising the fusion protein comprising the IL-2 protein and the CD80 protein of the present invention can be applied to all cells to which radiation therapy can be applied, and is particularly useful for enhancing the radiation sensitivity of cancer cells. It is preferable to use
- the pharmaceutical composition for enhancing radiation therapy exhibits a synergistic effect in cancer treatment when used in combination with radiation therapy, it may be used in the same context as an anticancer therapy adjuvant, a radiation therapy adjuvant, a radiation therapy enhancer, or a radiation sensitizer.
- the term "adjuvant” serves to enhance the effect of an agent, material, method, etc. having a therapeutic effect, and has therapeutic activity when administered with the pharmaceutical composition for enhancing radiation therapy according to the present invention. It means to increase the anticancer activity by enhancing the anticancer activity of the active ingredient or reducing side effects. Specifically, when combined with an anticancer agent or radiation, which is a conventional cancer treatment method, it may exhibit a synergistic effect on the cancer treatment effect, and may enhance the sensitivity of cancer cells to the anticancer agent or radiation.
- the fusion protein dimer was effective in enhancing the anticancer effect of radiation therapy not only in the radiation-irradiated site but also in the remote site not irradiated with radiation. Therefore, it can be used as a combination therapy to enhance the effect of radiotherapy.
- the fusion protein comprising the IL-2 protein and the CD80 protein included in the pharmaceutical composition for enhancing radiation therapy is as described below.
- Fusion protein comprising IL-2 protein and CD80 protein
- IL-2 or "interleukin-2” includes, unless otherwise stated, mammals, including primates (eg, humans) and rodents (eg, mice and rats). means any wild-type IL-2 obtained from any vertebrate source.
- the IL-2 may be obtained from animal cells, but includes those obtained from recombinant cells capable of producing IL-2.
- the IL-2 may be wild-type IL-2 or a mutant thereof.
- IL-2 or a variant thereof is collectively referred to as "IL-2 protein” or "IL-2 polypeptide”.
- IL-2, IL-2 proteins, IL-2 polypeptides, and IL-2 variants specifically bind to, for example, the IL-2 receptor. This specific binding can be confirmed by methods known to those skilled in the art.
- the IL-2 may have the amino acid sequence of SEQ ID NO: 35 or SEQ ID NO: 36. Also, at this time, the IL-2 may be in a mature form. Specifically, the mature IL-2 may not include a signal sequence, and may have the amino acid sequence of SEQ ID NO: 10. In this case, the IL-2 may be used as a concept including a fragment in which a portion of the N-terminus or C-terminus of wild-type IL-2 is truncated.
- the IL-2 fragment is 1, 2, 3, 4, 5, 6, 7, 8 consecutively from the N-terminus of the protein having the amino acid sequence of SEQ ID NO: 35 or SEQ ID NO: 36 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids may be deleted.
- the IL-2 fragment is 1, 2, 3, 4, 5, 6, 7, 8 consecutively from the C terminus of the protein having the amino acid sequence of SEQ ID NO: 35 or SEQ ID NO: 36 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 It may be in the form in which the amino acids of the dog are deleted.
- the term "IL-2 mutant” refers to a form in which some amino acids of full-length IL-2 or the aforementioned fragment of IL-2 are substituted. That is, the IL-2 variant may have an amino acid sequence different from that of wild-type IL-2 or a fragment thereof. However, the IL-2 variant may have an activity equivalent to or similar to that of wild-type IL-2.
- IL-2 activity may refer to, for example, specific binding to an IL-2 receptor, and this specific binding may be measured by a method known to those skilled in the art.
- the IL-2 mutant may be one in which a portion of the amino acid of wild-type IL-2 is substituted.
- the IL-2 variant by amino acid substitution at least one of the 38th, 42nd, 45th, 61st, and 72nd amino acids in the amino acid sequence of SEQ ID NO: 10 may be substituted.
- the IL-2 variant may be one in which at least one of the 38th, 42nd, 45th, 61st, or 72nd amino acids in the amino acid sequence of SEQ ID NO: 10 is substituted with another amino acid.
- IL-2 when IL-2 is a form in which a portion of the N-terminus of the amino acid sequence of SEQ ID NO: 35 is deleted, an amino acid at a complementary position in the amino acid sequence of SEQ ID NO: 10 may be substituted with another amino acid.
- the IL-2 variant is selected from among the 58th, 62nd, 65th, 81st, or 92th amino acids in the amino acid sequence of SEQ ID NO: 35.
- At least one may be substituted with another amino acid. These correspond to the 38th, 42nd, 45th, 61st, and 72th amino acid residues, respectively, of the amino acid sequence of SEQ ID NO: 10, respectively. According to one embodiment, as long as IL-2 activity is maintained, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids may be substituted. have. According to another embodiment, from 1 to 5 amino acids may be substituted.
- the IL-2 variant may be in a form in which two amino acids are substituted. Specifically, the IL-2 variant may be one in which the 38th and 42nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th and 45th amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th and 61st amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be one in which the 42nd and 45th amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 42nd and 61st amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 42nd and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 45th and 61st amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be one in which the 45th and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 61st and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be in a form in which three amino acids are substituted. Specifically, the IL-2 variant may be one in which the 38th, 42nd and 45th amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th, 42nd and 61st amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th, 42nd and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th, 45th, and 61st amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be one in which the 38th, 45th and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th, 61st, and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 42nd, 45th and 61st amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 42nd, 45th and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 45th, 61st, and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be in a form in which four amino acids are substituted. Specifically, the IL-2 variant may be one in which the 38th, 42nd, 45th and 61st amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th, 42nd, 45th and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10. Also, in one embodiment, the IL-2 variant may be one in which the 38th, 45th, 61st and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be one in which the 38th, 42nd, 61st and 72nd amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be one in which the 42 th, 45 th, 61 th and 72 th amino acids are substituted in the amino acid sequence of SEQ ID NO: 10.
- the IL-2 variant may be in a form in which five amino acids are substituted.
- the IL-2 variant may be one in which all of the 38th, 42nd, 45th, 61st, and 72th amino acids in the amino acid sequence of SEQ ID NO: 10 are substituted with other amino acids.
- the "other amino acids" introduced by the substitution are alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine. , histidine, isoleucine, leucine, lysine, methionine, phenyl alanine, proline, serine, threonine, tryptophan ( tryptophan), tyrosine (tyrosine) and valine (valine) may be any one selected from the group consisting of.
- the 38th position in the amino acid sequence of SEQ ID NO: 10 cannot be substituted with arginine
- the 42nd position cannot be substituted with phenylalanine
- the 45th position cannot be substituted with tyrosine.
- the 61st position cannot be substituted with glutamic acid
- the 72nd position cannot be substituted with leucine.
- arginine which is the 38th amino acid in the amino acid sequence of SEQ ID NO: 10 may be substituted with an amino acid other than arginine.
- arginine which is the 38th amino acid in the amino acid sequence of SEQ ID NO: 10 may be substituted with alanine (R38A).
- phenylalanine which is the 42nd amino acid in the amino acid sequence of SEQ ID NO: 10
- phenylalanine which is the 42nd amino acid in the amino acid sequence of SEQ ID NO: 10
- phenylalanine which is the 42nd amino acid in the amino acid sequence of SEQ ID NO: 10
- alanine F42A
- tyrosine which is the 45th amino acid in the amino acid sequence of SEQ ID NO: 10 may be substituted with an amino acid other than tyrosine.
- tyrosine which is the 45th amino acid in the amino acid sequence of SEQ ID NO: 10 may be substituted with alanine (Y45A).
- glutamic acid which is the 61st amino acid in the amino acid sequence of SEQ ID NO: 10
- glutamic acid which is the 61st amino acid in the amino acid sequence of SEQ ID NO: 10
- glutamic acid which is the 61st amino acid in the amino acid sequence of SEQ ID NO: 10
- glutamic acid which is the 61st amino acid in the amino acid sequence of SEQ ID NO: 10
- glutamic acid which is the 61st amino acid in the amino acid sequence of SEQ ID NO: 10
- E61R arginine
- leucine which is the 72nd amino acid in the amino acid sequence of SEQ ID NO: 10
- an amino acid other than leucine Preferably, in the amino acid substitution of the IL-2 variant, leucine, which is the 72nd amino acid in the amino acid sequence of SEQ ID NO: 10, may be substituted with glycine (L72G).
- the IL-2 variant may have at least one substitution selected from the group consisting of R38A, F42A, Y45A, E61R and L72G in the amino acid sequence of SEQ ID NO: 10.
- amino acid substitutions may occur at two, three, four or five positions at positions selected from the group consisting of R38A, F42A, Y45A, E61R and L72G.
- the IL-2 variant may be in a form in which two amino acids are substituted.
- the IL-2 mutant may be substituted with R38A and F42A.
- the IL-2 mutant may be substituted with R38A and Y45A.
- the IL-2 mutant may be substituted with R38A and E61R.
- the IL-2 mutant may be substituted with R38A and L72G.
- the IL-2 mutant may be substituted with F42A and Y45A.
- the IL-2 mutant may be substituted with F42A and E61R.
- the IL-2 mutant may be substituted with F42A and L72G.
- the IL-2 mutant may be substituted with E61R and L72G.
- the IL-2 variant may be in a form in which three amino acids are substituted.
- the IL-2 mutant may be substituted with R38A, F42A and Y45A.
- the IL-2 mutant may be substituted with R38A, F42A and E61R.
- the IL-2 mutant may be substituted with R38A, F42A and L72G.
- the IL-2 mutant may be substituted with R38A, Y45A, or E61R.
- the IL-2 variant may be substituted with R38A, Y45A and L72G.
- the IL-2 mutant may be substituted with F42A, Y45A and E61R.
- the IL-2 mutant may be substituted with F42A, Y45A and L72G. Also, in one embodiment, the IL-2 mutant may be substituted with F42A, E61R and L72G. Also, in one embodiment, the IL-2 mutant may be substituted with Y45A, E61R and L72G.
- the IL-2 variant may be in a form in which four amino acids are substituted.
- the IL-2 mutant may be substituted with R38A, F42A, Y45A and E61R.
- the IL-2 mutant may be substituted with R38A, F42A, Y45A and L72G.
- the IL-2 mutant may be substituted with R38A, F42A, E61R and L72G.
- the IL-2 variant may be substituted with R38A, Y45A, E61R and L72G.
- the IL-2 mutant may be substituted with F42A, Y45A, E61R and L72G.
- the IL-2 mutant may be substituted with R38A, F42A, Y45A, E61R and L72G.
- any one combination selected from the following (a) to (d) combinations may be substituted in the amino acid sequence of SEQ ID NO: 10:
- IL-2 when IL-2 has the amino acid sequence of SEQ ID NO: 35, it may have an amino acid substitution at a position complementary to SEQ ID NO: 10. Also, even when IL-2 is a fragment of the amino acid sequence of SEQ ID NO: 35, amino acids at positions complementary to those of SEQ ID NO: 10 may be substituted.
- the IL-2 variant may have the amino acid sequence of SEQ ID NO: 6, 22, 23 or 24.
- the IL-2 variant may be characterized in that it has low toxicity in vivo.
- the low toxicity in the living body may be a side effect caused by binding of IL-2 to the alpha chain (IL-2R ⁇ ) of the IL-2 receptor.
- IL-2R ⁇ alpha chain
- Various IL-2 variants have been developed to improve the side effects caused by the IL-2 and IL-2R ⁇ binding, and these IL-2 variants are those disclosed in U.S. Patent No. 5,229,109 and Korean Patent Publication No. 10-1667096B1.
- the IL-2 variant described in the present application has low in vivo toxicity compared to wild-type IL-2 due to low binding affinity to the alpha chain (IL-2R ⁇ ) of the IL-2 receptor.
- CD80 As used herein, the term “CD80”, also called “B7-1”, is a membrane protein present in dendritic cells, activated B cells, and monocytes. CD80 provides a costimulatory signal essential for T cell activation and survival. CD80 is known as a ligand for CD28 and CTLA-4, two different proteins present on the T cell surface. CD80 is composed of 288 amino acids, and specifically may have the amino acid sequence of SEQ ID NO: 11. Also, as used herein, "CD80 protein” refers to a full-length CD80 or CD80 fragment.
- CD80 fragment refers to a truncated form of CD80.
- the CD80 fragment may be an extracellular domain of CD80.
- the 1st to 34th amino acids may be excluded from the N-terminus, which is the signal sequence of CD80.
- one embodiment of the CD80 fragment may be a protein composed of amino acids 35 to 288 of SEQ ID NO: 11.
- one embodiment of the CD80 fragment may be a protein composed of amino acids 35 to 242 of SEQ ID NO: 11.
- one embodiment of the CD80 fragment may be a protein composed of amino acids 35 to 232 of SEQ ID NO: 11.
- one embodiment of the CD80 fragment may be a protein consisting of amino acids 35 to 139 of SEQ ID NO: 11. In addition, one embodiment of the CD80 fragment may be a protein consisting of amino acids 142 to 242 of SEQ ID NO: 11. In one embodiment, the CD80 fragment may have the amino acid sequence of SEQ ID NO: 2.
- the IL-2 protein and the CD80 protein may be bound by a linker or a carrier.
- the IL-2 or variant thereof and the CD80(B7-1) or fragment thereof may be bound by a linker or a carrier.
- linker and carrier are also used interchangeably.
- the linker connects two proteins.
- One embodiment of the linker may include 1 to 50 amino acids, albumin or a fragment thereof, or an Fc domain of an immunoglobulin.
- the Fc domain of the immunoglobulin includes the heavy chain constant region 2 (CH2) and the heavy chain constant region 3 (CH3) of the immunoglobulin, and includes the variable regions and the light chain constant region 1 (CH1) of the heavy and light chains of the immunoglobulin protein that does not
- the immunoglobulin may be IgG, IgA, IgE, IgD or IgM, preferably IgG4.
- the Fc domain of wild-type immunoglobulin G4 may have the amino acid sequence of SEQ ID NO: 4.
- the Fc domain of the immunoglobulin may be a wild-type Fc domain as well as an Fc domain variant.
- the term "Fc domain variant" as used herein is different from the glycosylation pattern of the wild-type Fc domain, increased sugar chains compared to the wild-type Fc domain, decreased sugar chains compared to the wild-type Fc domain, or the sugar chains are removed ( It may be in a deglycosylated form.
- an aglycosylated Fc domain is also included.
- the Fc domain or variant may have a number of sialic acid, fucosylation, and glycosylation adjusted through culture conditions or host genetic manipulation.
- the sugar chain of the Fc domain of an immunoglobulin can be modified by a conventional method such as a chemical method, an enzymatic method, and a genetic engineering method using microorganisms.
- the Fc domain variant may be a mixed form of the immunoglobulin Fc region of IgG, IgA, IgE, IgD or IgM.
- the Fc domain variant may be a form in which some amino acids of the Fc domain are substituted with other amino acids.
- One embodiment of the Fc domain variant may have the amino acid sequence of SEQ ID NO: 12.
- the fusion protein may have a structure in which CD80 and IL-2 proteins are linked or IL-2 and CD80 are linked to their N-terminus and C-terminus, respectively, using the Fc domain as a linker (or carrier).
- the N-terminus or C-terminus of the Fc domain and CD-80 or IL-2 may optionally be connected by a linker peptide.
- the fusion protein may be of the following structural formula (I) or (II):
- the N' is the N-terminus of the fusion protein
- X is a CD80 protein
- Y is an IL-2 protein
- linker (1) and linker (2) are peptide linkers
- n and m are each independently O or 1.
- the fusion protein may be of structural formula (I).
- the IL-2 protein is as described above.
- the CD80 protein is as described above.
- the IL-2 protein may be an IL-2 variant in which one to five amino acids are substituted as compared to wild-type IL-2.
- the CD80 protein may be a fragment in which up to about 34 consecutive amino acid residues are truncated from the N-terminus or C-terminus of wild-type CD80.
- the CD protein may be an extracellular immunoglobulin-like domain having an activity of binding to the T cell surface receptors CTLA-4 and CD28.
- the fusion protein may have the amino acid sequence of SEQ ID NO: 9, 26, 28 or 30.
- the fusion protein is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% of the amino acid sequence of SEQ ID NO: 9, 26, 28 or 30. , 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
- identity for example, percent homology, may be determined through homology comparison software such as BlastN software of the National Center of Biotechnology Information (NCBI).
- a peptide linker (1) may be included between the CD80 protein and the Fc domain.
- the peptide linker (1) may consist of 5 to 80 consecutive amino acids, 20 to 60 consecutive amino acids, or 25 to 50 consecutive amino acids, or 30 to 40 amino acids. In one embodiment, the peptide linker (1) may consist of 30 amino acids.
- the peptide linker (1) may include at least one cysteine. Specifically, it may contain one, two or three cysteines.
- the peptide linker (1) may be derived from the hinge of an immunoglobulin.
- the peptide linker (1) may be a peptide linker consisting of the amino acid sequence of SEQ ID NO: 3.
- the peptide linker (2) may consist of 1 to 50 consecutive amino acids, or 3 to 30 consecutive amino acids, or 5 to 15 amino acids.
- the peptide linker (2) may be (G4S)n (in this case, n is an integer of 1 to 10). In this case, in (G4S)n, n may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
- the peptide linker (2) may be a peptide linker consisting of the amino acid sequence of SEQ ID NO: 5.
- the fusion protein may be a dimer in which two fusion proteins comprising the IL-2 or variant thereof and CD80 or a fragment thereof are bound.
- the fusion protein comprising the IL-2 or variant thereof and CD80 or a fragment thereof is as described above.
- the bond between the fusion proteins constituting the dimer may be formed by a disulfide bond by a cysteine present in the linker, but is not limited thereto.
- the fusion proteins constituting the dimer may be the same, but may be different fusion proteins.
- the dimer may be a homodimer.
- An embodiment of the fusion protein constituting the dimer may be a protein having the amino acid sequence of SEQ ID NO: 9.
- composition for enhancing radiation therapy of the present invention comprising a fusion protein comprising the IL-2 protein and the CD80 protein can be additionally administered in combination with other anticancer agents, thereby further enhancing the radiation therapy effect on cancer. can do it
- the anti-cancer agent may be a chemical anti-cancer agent, a targeted anti-cancer agent, or an immuno-cancer agent.
- the "chemotherapy agent” is not limited thereto, but may be an alkylating agent, a microtubule inhibitor, an antimetbolite, or a topoisomerase inhibitor.
- the alkylating agent is mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine ), procarbazine, busulfan, streptozocin, carmustine, iomustine, dacarbazine, cisplatin, carboplatin ( carboplatin), but may be oxaliplatin (oxaliplatin), but is not limited thereto.
- the microtubule inhibitor may be docetaxel, vinblastine, oncovin, or vinorelbine, but is not limited thereto.
- the antagonist is fluorouracil, capecitabine, cytarabine, gemcitabine, fludarabine, methotrexate, pemetrexed, It may be mercaptopurine (mercaptopurine), but is not limited thereto.
- the topoisomerase inhibitor may be hycamtin, camptosar, vepesid, taxol, bleomycin, adriamycin, or cerubidine. , but is not limited thereto.
- targeted anticancer agent is, but not limited to, trastuzumab, pertuzumab, panitumumab, cetuximab, bevacizumab, ramucirumab (ramucirumab), aflibercept, rituximab, obinutuzumab, daratumumab, denosumab, ibrutinib, dasatinib (dasatinib), nilotinib, imatinib, bosutinib, osimertinib, erlotinib, gefitinib, nintedanib, suniti Nib (sunitinib), sorafenib (sorafenib), cabozantinib (cabozantinib), lenvatinib (lenvatinib), regorafenib (regorafenib), axitinib
- the "immuno-cancer agent” is not limited thereto, but may be an immune checkpoint inhibitor, an immune cell therapeutic agent (CAR-T), an antibody drug conjugate (ADC), a dual antibody, an anti-cancer virus, or an anti-cancer vaccine.
- the immune checkpoint inhibitor may be a PD-1 antibody, a PD-L1 antibody, a CTLA-4 antibody, a TIM3 antibody, or a LAG3 antibody.
- the PD-1 antibody may be pembrolizumab, nivolumab, or semiplimab, and the PD-L1 antibody is atezolizumab, avelumab, or durvallu. It may be durvalumab, but is not limited thereto.
- the CTLA-4 antibody may be ipilimumab or tremelimumab
- the TIM3 antibody may be MBG452
- the LAG3 antibody may be BMS-986016 or LAG525, but is not limited thereto.
- the immune cell therapeutic agent may be tisagenlecleucel or axicabtagene ciloleucel, but is not limited thereto.
- the ADC is gemtuzumab-ozogamicin, brentuximab vedotin, trastuzumab emtansine, inotuzumab ozogamicin, eribulin mesylate ( eribulin mesylate), but is not limited thereto.
- the dual antibody may be blinatumomab
- the anti-cancer virus may be talimogene laherparepvec
- the anti-cancer vaccine may be sipuleucel-T,
- the present invention is not limited thereto.
- the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may be any non-toxic material suitable for delivery to a patient. Distilled water, alcohol, fats, waxes and inert solids may be included as carriers. Pharmaceutically acceptable adjuvants (buffers, dispersants) may also be included in the pharmaceutical composition.
- the pharmaceutical composition may be prepared as a parenteral formulation according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier.
- pharmaceutically acceptable means that it does not inhibit the activity of the active ingredient and does not have toxicity beyond what the application (prescription) target can adapt.
- the pharmaceutical composition When the pharmaceutical composition is prepared for parenteral use, it may be formulated in the form of injections, transdermal administrations, nasal inhalants and suppositories together with suitable carriers according to methods known in the art.
- a suitable carrier may be sterile water, ethanol, polyol such as glycerol or propylene glycol, or a mixture thereof, preferably Ringer's solution, PBS (phosphate buffered saline) containing triethanolamine, or sterilized for injection. Water, an isotonic solution such as 5% dextrose, etc. may be used.
- Formulation of pharmaceutical compositions is known in the art, and specifically, reference may be made to the literature [Remington's Pharmaceutical Sciences (19th ed., 1995)] and the like. This document is considered a part of this specification.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- administration refers to introducing a predetermined substance to an individual by an appropriate method, and the administration route of the composition may be administered through any general route as long as it can reach a target tissue.
- Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration may be administered intrarectally, but is not limited thereto.
- the term "individual” refers to all animals including humans, rats, mice, livestock, and the like. Preferably, it may be a mammal including a human.
- the term "pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not to cause side effects, and the effective dose level is determined by the patient's gender, age, and weight. , health condition, disease type, severity, drug activity, sensitivity to drug, administration method, administration time, administration route, and excretion rate, treatment period, factors including drugs used in combination or concomitantly, and other medical fields. It can be readily determined by one of ordinary skill in the art according to known factors.
- the daily dose may be in the range of 0.01 ⁇ g/kg to 10 g/kg, or in the range of 0.01 mg/kg to 1 g/kg. Administration may be performed once or divided into several times a day. These dosages should not be construed as limiting the scope of the invention in any respect.
- Another aspect of the present invention comprises the steps of: irradiating radiation to a cancer site of a mammal other than a human suffering from cancer; and administering the pharmaceutical composition for enhancing radiation therapy according to the present invention to the mammal; provides a radiation therapy method for cancer comprising.
- the term "irradiation” refers to a local treatment method that damages the DNA of malignant cells by irradiating radiation. Normal cells have a greater capacity to repair this damage than tumor cells. Irradiation refers to a treatment using such a difference, and includes a method of treatment using radiation in a conventional sense.
- the radiation can be divided into radical radiation therapy, adjuvant radiation therapy, and palliative radiation therapy according to the purpose of radiation therapy.
- Curative radiation therapy refers to radiation therapy for the purpose of cure when the tumor is relatively limited to a local area and there is no distant metastasis.
- Adjuvant radiation therapy refers to radiation therapy performed for the purpose of preventing local recurrence after surgery. By combining radiation therapy, it is possible to not only reduce recurrence, but also reduce the scope of surgery to maintain tissue function.
- Palliative radiation therapy is radiation therapy performed for the purpose of relieving symptoms caused by cancer. Radiation is a treatment that uses high-energy radiation to kill cancer cells, but since it affects not only cancer cells but also normal tissues around them, side effects may occur due to treatment. Examples include skin changes, hair loss, nausea and vomiting, diarrhea, mucositis/esophagitis, dry mouth, and changes in reproductive function.
- the radiation may be single-irradiated or fractionally irradiated with an irradiation amount of 0.1 Gy to 100 Gy.
- the radiation dose is not limited thereto, but may be 0.1 Gy to 100 Gy, 0.5 Gy to 90 Gy, 0.7 Gy to 80 Gy, 0.9 Gy to 70 Gy, and preferably 1 Gy to 60 Gy.
- the radiation may be irradiated for a period of 1 to 26 weeks, but is not limited thereto.
- the pharmaceutical composition for promoting radiation therapy according to the present invention may be administered in combination with radiation irradiation during the treatment of cancer in order to obtain a radiation therapy enhancement effect for cancer, and the "administered in combination” is used to treat various types of cancer cells. It refers to the combination of irradiation with radiation during the anticancer process.
- treatment may be used to include both therapeutic treatment and prophylactic treatment.
- prevention may be used in the sense of alleviating or reducing a pathological condition or disease of an individual.
- treatment includes any form of administration or application for treating a disease in mammals including humans. The term includes inhibiting or slowing the progression of a disease or disorder; restoring or repairing damaged or missing function, thereby partially or completely alleviating the disease; or stimulate inefficient processes; It includes the meaning of alleviating serious diseases.
- treatment may include, without limitation, any action that improves or benefits cancer symptoms by irradiating radiation.
- prevention may include, without limitation, any action that blocks cancer symptoms or suppresses or delays cancer symptoms using the pharmaceutical composition of the present invention.
- the radiation therapy effect when irradiating radiation before and after administration of the pharmaceutical composition for enhancing radiation therapy of the present invention, can be significantly enhanced according to a synergistic effect. Furthermore, resistance to anticancer drugs or cancer metastasis or recurrence can be prevented.
- the pharmaceutical composition may be administered with a time gap before or after irradiation.
- the administration time of the pharmaceutical composition may be appropriately increased or decreased depending on the type of cancer, the degree of cancer progression, the route of administration, sex, age, body weight, and the like.
- a daily dose may be regularly administered, or an intensively large amount may be administered in a short period of time.
- the pharmaceutical composition is not limited thereto, but once a week to 20 times, 1 to 18 times, 1 to 15 times, 1 to 10 times, 1 to 8 times, 1 to 5 times, Alternatively, it may be administered 2 to 3 times.
- the pharmaceutical composition is not limited thereto, but may be administered before and after 6 to 48 hours, 10 to 42 hours, 14 to 36 hours, or 18 to 30 hours based on the time of irradiation, preferably may be administered before or after 20 to 28 hours.
- the route of administration of the composition of the present invention may be administered through various routes, either oral or parenteral, as long as it can reach the target tissue, and specifically, oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, It may be administered in a conventional manner via transdermal, intranasal, inhalation, intraocular or intradermal routes.
- the radiation therapy method for cancer of the present invention includes administering a therapeutically effective amount of the pharmaceutical composition for enhancing radiation therapy according to the present invention.
- the therapeutically effective amount means an amount that effectively enhances the sensitivity of a tumor in cancer cells to radiation. It is apparent to those skilled in the art that a suitable total daily amount can be determined by a treating physician within the scope of sound medical judgment.
- a specific therapeutically effective amount for a particular patient will depend on the type and extent of the response to be achieved, the specific composition, including whether other agents are used, if necessary, the patient's age, weight, general health, sex and diet, time of administration; It is preferable to apply differently depending on various factors including the route of administration and secretion rate of the composition, the duration of treatment, and the radiation dose to be irradiated, and similar factors well known in the pharmaceutical field. Therefore, the effective amount of the pharmaceutical composition for promoting radiation therapy suitable for the purpose of the present invention is preferably determined in consideration of the above.
- a known anticancer agent may be administered in combination with the pharmaceutical composition for enhancing radiation therapy of the present invention to enhance the anticancer effect including the radiation treatment effect.
- the radiation treatment method of the present invention is applicable to any animal in which radiation resistance can be increased.
- Animals include humans and primates, as well as domestic animals such as cattle, pigs, sheep, horses, dogs and cats.
- the radiation treatment method of the present invention can be used to treat all cancers with increased radiation resistance.
- the radiation treatment method of the present invention comprises administering the composition of the present invention to an individual having cancer cells or an individual suffering from cancer, and irradiating the radiation, wherein the radiation is ionizing radiation, in particular, a commonly used linear accelerator. It may refer to gamma radiation emitted by (linear accelerators) or radionuclides (radionuclides).
- a commonly used linear accelerator it may refer to gamma radiation emitted by (linear accelerators) or radionuclides (radionuclides).
- Irradiation by radionuclides can be made externally or internally, and the amount of the anticancer agent administered, the radiation dose, and the intermittent radiation dose depend on a series of factors such as the type, location of the tumor, and the patient's response to chemotherapy or radiation therapy. It may vary by variables.
- the radiation therapy method of the present invention includes brachytherapy, radionuclide therapy, external beam radiation therapy, hyperthermia (including cryoablation therapy and hyperthermia therapy), radiosurgery, and charged-particle radiation therapy (charged-particle radiation therapy). particle radiotherapy), neutron radiation therapy, and photodynamic therapy.
- a fusion protein comprising a human CD80 fragment, an Fc domain and an IL-2 variant, a CD80 fragment (SEQ ID NO: 2), an Ig hinge (SEQ ID NO: 3), an Fc domain (SEQ ID NO: 4), a linker (SEQ ID NO: 5) ) and two amino acids substituted IL-2 variant (2M) (R38A, F42A) (SEQ ID NO: 6) of SEQ ID NO: 9 comprising in this order from the N-terminus
- a dimer containing the fusion protein was prepared.
- a specific manufacturing method was performed by the method described in Korean Patent Application Laid-Open No. 10-2020-0032009A.
- the fusion protein dimer was named "GI-101".
- a fusion protein comprising mouse CD80, Fc domain and IL-2 variant, mCD80 fragment (SEQ ID NO: 13), Ig hinge (SEQ ID NO: 3), Fc domain (SEQ ID NO: 4), linker (SEQ ID NO: 5)
- a dimer comprising the fusion protein of SEQ ID NO: 38 including two amino acids substituted IL-2 variant (2M) (R38A, F42A) (SEQ ID NO: 6) in this order from the N-terminus was prepared.
- the fusion protein dimer was named "mGI-101".
- test substance in the frozen state was completely thawed at room temperature, and then prepared according to the administration dose and volume using PBS as a vehicle. After mixing the test substance and PBS, it was administered after gentle hand agitation without vortexing or pipetting. The thawed test substance was continuously stored in refrigeration until administration.
- the B16F10 cell line a mouse melanoma cell line, was purchased from the Korea Cell Line Bank and cultured at 37° C. and 5% CO 2 condition using Dulbecco's modified MEM medium containing 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- tail marking was done on the tail of the mice using a red oil pen, and a temporary individual identification card (test name, individual number, delivery time) was attached to the breeding box during quarantine and acclimatization periods.
- a temporary individual identification card (test name, individual number, delivery time) was attached to the breeding box during quarantine and acclimatization periods.
- each individual was marked with a black oil pen on the tail of the mouse, and an individual identification card (test name, group information, individual number, gender, wearing time, administration period) was attached to each cage.
- the tumor size of C57BL/6 mice was measured using an electronic caliper, and then, 10 mice per group were divided into 5 groups in total. Specifically, when the tumor volume of most of the individuals transplanted with the tumor cell line reached about 50 ⁇ 120 mm 3 , the tumors transplanted on both sides of one individual were measured, and group separation was performed according to the Z-array method based on the tumor size of the average value. carried out.
- C57BL/6 mice the subjects of the experiment, were bred in a polycarbonate breeding box with a size of 200 (Width, mm) ⁇ 260 (Depth, mm) ⁇ 130 (Height, mm), 5 per box.
- breeding temperature conditions were 20 °C ⁇ 25 °C
- humidity was 50 ⁇ 20%.
- Ventilation was performed 10 to 15 times per hour, and a 12-hour day/night cycle was maintained, and at this time, the illuminance was 150-300 Lux.
- feed and water were allowed to be freely consumed.
- tap water was filtered with a filter oil-water sterilizer, irradiated with ultraviolet rays, and provided using a polycarbonate drinking water bottle (250 ml).
- the breeding box and feeder were exchanged at a frequency of once/week, and a water bottle at a frequency of 2 times/week.
- the breeding equipment was washed with a disinfectant solution, disinfected using an ultraviolet sterilizer, and then reused.
- mGI-101 prepared in Preparation Example 1 was administered to a mouse tumor model through intraperitoneal injection, and the mice were 8 weeks old at the time of administration. Specifically, in the case of experimental groups G2 and G4, mGI-101 was first administered on the day of group separation (day 1), and in the case of experimental group G5, mGI-101 was first administered on day 4, the day after irradiation. Thereafter, mGI-101 was additionally administered intraperitoneally to the experimental groups G2, G4 and G5 once a week, twice in total. In the case of control group G1, PBS was administered on the day of group separation (day 1), and then PBS was additionally administered through intraperitoneal injection once a week, a total of 2 times.
- Tumor volume (mm3) [L(mm) ⁇ W(mm) ⁇ W(mm)] ⁇ 0.5
- TGI tumor growth inhibition
- TGI (1-(T i -T 0 )/(V i -V 0 )) ⁇ 100
- T i the volume of the tumor before administration in the experimental group
- T 0 tumor volume after administration of the experimental group
- V i volume of tumor before administration of control group
- V 0 volume of tumor after administration of control group
- the tumor volume before administration of each individual was set as a value measured when group separation was performed.
- G3 significantly inhibited tumor growth compared to G1 and G2 on day 15
- both G4 and G5 significantly inhibited tumor growth compared to G1 and G2 on days 11 and 15 ( 1a and 2a-2e).
- G2 significantly inhibited tumor growth compared to G1 on day 15, and G4 significantly inhibited tumor growth on day 15 compared to G1 and G3.
- G5 significantly inhibited tumor growth compared to G1 and G3 on day 11, and significantly inhibited tumor growth compared to G1, G2, and G3 on day 15 ( FIGS. 1B and 3A to 3E ).
- Tumor growth inhibition (TGI) for the right tumor irradiated with radiation was found to be 1 mouse with 30% or more inhibition, 1 animal with 50% or more inhibition, and 0 mice with 80% or more inhibition for G1. , 4 animals with more than 30% inhibition, 3 animals with more than 50% inhibition, and 0 animals with more than 80% inhibition. In the case of G3, 5 mice with more than 30% inhibition, 4 mice with more than 50% inhibition, and 2 mice with more than 80% inhibition. In the case of G4, 7 animals with more than 30% inhibition, 6 animals with more than 50% inhibition, and more than 80% inhibition appeared as two. In the case of G5, 10 animals with more than 30% inhibition, 10 animals with more than 50% inhibition, and 4 mice with more than 80% inhibition (FIG. 4a and Table 2).
- the tumor growth inhibition rate for the left non-irradiated tumor was 0 mice with more than 30% inhibition, 0 mice with more than 50% inhibition, and 0 mice with more than 80% inhibition for G1, and for G2, more than 30% inhibition 5 animals, 2 mice with more than 50% inhibition, and 2 mice with more than 80% inhibition.
- G3 there were 0 mice with more than 30% inhibition, 0 animals with more than 50% inhibition, and 0 animals with more than 80% inhibition. appeared as 0.
- G5 8 mice with more than 30% inhibition, 6 animals with more than 50% inhibition, and 4 mice with more than 80% inhibition (Fig. 4b and Table 3).
- the tumor growth inhibition rates for the bilateral tumor averages were 1 mice with more than 30% inhibition, 0 mice with more than 50% inhibition, and 0 mice with more than 80% inhibition for G1, and for G2, 4 mice with more than 30% inhibition, 50% 2 mice with abnormal inhibition and 2 mice with more than 80% inhibition.
- G5 10 animals with more than 30% inhibition, 7 animals with more than 50% inhibition, and 4 mice with more than 80% inhibition (Fig. 4c and Table 4).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
Abstract
Description
군(group) | 시험물질 | 시험물질 투여시기* | 투여용량 및 조사량 | 투여 부피 (volume) |
투여 경로 | 투여횟수 | 투여기간 | 개체수 |
G1 (대조군) |
PBS(Vehicle) | Day 1 | - | 10 mL/㎏ | 복강주사 | 주 1회 (총 2회) |
2주 | 10 |
G2 | mGI-101 | Day 1 | 3 ㎎/㎏ | 10 mL/㎏ | 복강주사 | 주 1회 (총 2회) |
2주 | 10 |
G3 | 방사선 | Day 3 | 6 Gy | - | 조사 | 단회 | - | 10 |
G4(병용: mGI-101→방사선) | mGI-101 | Day 1 | 3 ㎎/㎏ | 10 mL/㎏ | 복강주사 | 주 1회 (총 2회) |
2주 | 10 |
방사선 | Day 3 | 6 Gy | - | 조사 | 단회 | |||
G5(병용: 방사선→mGI-101) | 방사선 | Day 3 | 6 Gy | - | 조사 | 단회 | 2주 | 10 |
mGI-101 | Day 4 | 3 ㎎/㎏ | 10 mL/㎏ | 복강주사 | 주 1회 (총 2회) |
군(group) | 30% 이상 억제 | 50% 이상 억제 | 80% 이상 억제 |
G1 | 1 | 1 | 0 |
G2 | 4 | 3 | 0 |
G3 | 5 | 4 | 2 |
G4 | 7 | 6 | 2 |
G5 | 10 | 10 | 4 |
군(group) | 30% 이상 억제 | 50% 이상 억제 | 80% 이상 억제 |
G1 | 0 | 0 | 0 |
G2 | 5 | 2 | 2 |
G3 | 0 | 0 | 0 |
G4 | 6 | 3 | 0 |
G5 | 8 | 6 | 4 |
군(group) | 30% 이상 억제 | 50% 이상 억제 | 80% 이상 억제 |
G1 | 1 | 0 | 0 |
G2 | 4 | 2 | 2 |
G3 | 1 | 0 | 0 |
G4 | 6 | 4 | 0 |
G5 | 10 | 7 | 4 |
Claims (26)
- IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질 이량체를 포함하는 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 IL-2 단백질 및 상기 CD80 단백질은 링커에 의해 결합된 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 IL-2 단백질은 서열번호 10의 아미노산 서열을 갖는 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 IL-2 단백질은 IL-2 변이체인 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제4항에 있어서,상기 IL-2 변이체는 서열번호 10의 아미노산 서열에서 38번째, 42번째, 45번째, 61번째 및 72번째 위치의 아미노산 중 적어도 하나가 치환된 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제4항에 있어서,상기 IL-2 변이체는 서열번호 10의 아미노산 서열에서 R38A, F42A, Y45A, E61R 및 L72G로 구성된 군으로부터 선택되는 적어도 어느 하나의 치환이 일어난 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제4항에 있어서,상기 IL-2 변이체는 서열번호 10의 아미노산 서열에서 하기 (a) 내지 (d) 조합 중 선택되는 어느 하나의 조합의 치환이 일어난 것인, 암에 대한 방사선 치료 증진용 약학적 조성물:(a) R38A/F42A(b) R38A/F42A/Y45A(c) R38A/F42A/E61R(d) R38A/F42A/L72G.
- 제4항에 있어서,상기 IL-2 변이체는 서열번호 6, 22, 23 또는 24의 아미노산 서열을 갖는 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 CD80은 서열번호 11의 아미노산 서열을 갖는 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 CD80 단백질은 CD80의 단편인 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제10항에 있어서,상기 CD80의 단편은 서열번호 11의 아미노산 서열 중 35번째 내지 242번째의 아미노산으로 이루어진 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제2항에 있어서,상기 링커는 알부민 또는 면역글로불린의 Fc 도메인인 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제12항에 있어서,상기 Fc 도메인은 야생형 또는 변이체인 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제12항에 있어서,상기 Fc 도메인은 서열번호 4의 아미노산 서열을 갖는 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제13항에 있어서,상기 Fc 도메인의 변이체는 서열번호 12의 아미노산 서열을 갖는 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 융합단백질은 하기 구조식(I) 또는 (II)로 이루어진 것인, 암에 대한 방사선 치료 증진용 약학적 조성물:N'-X-[링커(1)]n-Fc 도메인-[링커(2)]m-Y-C' (I)N'-Y-[링커(1)]n-Fc 도메인-[링커(2)]m-X-C' (II)이때, 상기 구조식(I) 및 (II)에 있어서,상기 N'은 융합단백질의 N-말단이고,상기 C'는 융합단백질의 C-말단이며,상기 X는 CD80 단백질이고,상기 Y는 IL-2 단백질이며,상기 링커(1) 및 링커(2)는 펩타이드 링커이고,상기 n 및 m은 각각 독립적으로, O 또는 1이다.
- 제16항에 있어서,상기 링커(1)이 서열번호 3의 아미노산 서열로 이루어진 펩타이드 링커인 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제16항에 있어서,상기 링커(2)가 서열번호 5의 아미노산 서열로 이루어진 펩타이드 링커인 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제16항에 있어서,상기 융합단백질은 구조식(I)로 이루어진 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 융합단백질은 서열번호 9, 26, 28 또는 30의 아미노산 서열에 대해 85% 혹은 그 이상의 서열동일성을 갖는 것인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 제1항에 있어서,상기 암은 위암, 간암, 폐암, 대장암, 유방암, 전립선암, 난소암, 췌장암, 자궁경부암, 갑상선암, 후두암, 급성 골수성 백혈병, 뇌종양, 신경모세포종, 망막 모세포종, 두경부암, 침샘암 및 림프종으로 구성된 군에서 선택되는 어느 하나인, 암에 대한 방사선 치료 증진용 약학적 조성물.
- 암에 걸린 인간을 제외한 포유동물의 암 부위에 방사선을 조사하는 단계; 및제1항 내지 제21항 중 어느 한 항의 약학적 조성물을 상기 포유동물에 투여하는 단계;를 포함하는 암에 대한 방사선 치료 방법.
- 제22항에 있어서,상기 방사선은 조사(irradiation)량을 0.1 Gy 내지 100 Gy로 조사하는 것인, 암에 대한 방사선 치료 방법.
- 제22항에 있어서,상기 약학적 조성물은 방사선 조사 전 또는 조사 후에 투여되는 것인, 암에 대한 방사선 치료 방법.
- 제24항에 있어서,상기 약학적 조성물은 방사선 조사 시점을 기준으로 6 내지 48시간 전후로 투여되는 것인, 암에 대한 방사선 치료 방법.
- 제22항에 있어서,상기 약학적 조성물은 주당 1회 내지 20회 투여되는 것인, 암에 대한 방사선 치료 방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022574506A JP2023529358A (ja) | 2020-06-05 | 2021-06-01 | Il-2タンパク質およびcd80タンパク質を含む融合タンパク質を含む、放射線療法を増強するための医薬組成物 |
US18/008,034 US20230233680A1 (en) | 2020-06-05 | 2021-06-01 | Pharmaceutical composition for enhancing radiotherapy comprising fusion protein containing il-2 protein and cd80 protein |
EP21817193.2A EP4162945A4 (en) | 2020-06-05 | 2021-06-01 | PHARMACEUTICAL COMPOSITION FOR IMPROVING RADIOTHERAPY COMPRISING A FUSION PROTEIN CONTAINING AN IL-2 PROTEIN AND A CD80 PROTEIN |
CN202180039926.XA CN115803045A (zh) | 2020-06-05 | 2021-06-01 | 用于增强放射治疗的包括含有il-2蛋白和cd80蛋白的融合蛋白的药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0068456 | 2020-06-05 | ||
KR1020200068456A KR102373965B1 (ko) | 2020-06-05 | 2020-06-05 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021246757A1 true WO2021246757A1 (ko) | 2021-12-09 |
Family
ID=78831156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/006809 WO2021246757A1 (ko) | 2020-06-05 | 2021-06-01 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230233680A1 (ko) |
EP (1) | EP4162945A4 (ko) |
JP (1) | JP2023529358A (ko) |
KR (2) | KR102373965B1 (ko) |
CN (1) | CN115803045A (ko) |
TW (1) | TW202203982A (ko) |
WO (1) | WO2021246757A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
KR20020010206A (ko) * | 2000-07-27 | 2002-02-04 | 이시우 | 인터루킨 12와 보조활성인자 b7.1 유전자를 함유하는dna 벡터 및 이벡터가 도입된 항암 세포백신 |
KR101667096B1 (ko) | 2011-02-10 | 2016-10-18 | 로슈 글리카트 아게 | 돌연변이 인터루킨-2 폴리펩티드 |
KR20160134989A (ko) * | 2015-05-14 | 2016-11-24 | 순천향대학교 산학협력단 | 인간 인터류킨-2 단백질을 포함하는 약학조성물 |
KR20180069903A (ko) * | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
KR20200032009A (ko) | 2018-09-17 | 2020-03-25 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
CN110256583B (zh) * | 2019-07-11 | 2022-05-20 | 中国科学院生物物理研究所 | 一种il-2突变体与抗体的融合蛋白及其应用 |
-
2020
- 2020-06-05 KR KR1020200068456A patent/KR102373965B1/ko active IP Right Grant
-
2021
- 2021-06-01 CN CN202180039926.XA patent/CN115803045A/zh active Pending
- 2021-06-01 JP JP2022574506A patent/JP2023529358A/ja active Pending
- 2021-06-01 EP EP21817193.2A patent/EP4162945A4/en active Pending
- 2021-06-01 WO PCT/KR2021/006809 patent/WO2021246757A1/ko active Application Filing
- 2021-06-01 US US18/008,034 patent/US20230233680A1/en active Pending
- 2021-06-04 TW TW110120470A patent/TW202203982A/zh unknown
-
2022
- 2022-01-27 KR KR1020220012346A patent/KR20220020304A/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
KR20020010206A (ko) * | 2000-07-27 | 2002-02-04 | 이시우 | 인터루킨 12와 보조활성인자 b7.1 유전자를 함유하는dna 벡터 및 이벡터가 도입된 항암 세포백신 |
KR101667096B1 (ko) | 2011-02-10 | 2016-10-18 | 로슈 글리카트 아게 | 돌연변이 인터루킨-2 폴리펩티드 |
KR20160134989A (ko) * | 2015-05-14 | 2016-11-24 | 순천향대학교 산학협력단 | 인간 인터류킨-2 단백질을 포함하는 약학조성물 |
KR20180069903A (ko) * | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
KR20200032009A (ko) | 2018-09-17 | 2020-03-25 | (주)지아이이노베이션 | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도 |
Non-Patent Citations (3)
Title |
---|
ONCOGENE, vol. 23, no. 8, 2004, pages 1599 - 1607 |
PALATA ONDREJ, HRADILOVA PODZIMKOVA NADA, NEDVEDOVA EVA, UMPRECHT ALEXANDRA, SADILKOVA LENKA, PALOVA JELINKOVA LENKA, SPISEK RADEK: "Radiotherapy in Combination With Cytokine Treatment", FRONTIERS IN ONCOLOGY, vol. 9, no. 367, pages 1 - 14, XP055876769, DOI: 10.3389/fonc.2019.00367 * |
See also references of EP4162945A4 |
Also Published As
Publication number | Publication date |
---|---|
TW202203982A (zh) | 2022-02-01 |
EP4162945A1 (en) | 2023-04-12 |
EP4162945A4 (en) | 2023-11-29 |
KR20220020304A (ko) | 2022-02-18 |
US20230233680A1 (en) | 2023-07-27 |
KR102373965B9 (ko) | 2022-12-05 |
CN115803045A (zh) | 2023-03-14 |
KR102373965B1 (ko) | 2022-03-15 |
KR20210151528A (ko) | 2021-12-14 |
JP2023529358A (ja) | 2023-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103458930B (zh) | 针对cd74的人抗体和抗体-药物缀合物 | |
EA023148B1 (ru) | Композиции на основе антагонистов pd-1 и их применение | |
CA2182289C (en) | Immuno-stimulatory monoclonal antibodies | |
JPH06501161A (ja) | 抗腫瘍免疫性の強化と遺伝子治療のための組成物及び方法 | |
WO2020055040A1 (en) | Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell | |
Jurin et al. | Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel | |
EA014644B1 (ru) | Способы защиты от апоптоза с применением липопептидов | |
CA3144985A1 (en) | Hdac6-activated macrophages, compositions, and uses thereof | |
US20190290759A1 (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer | |
WO2022182483A1 (en) | Methods for local and systemic treatment of cancers, tumors and tumor cells | |
US11857601B2 (en) | Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug | |
WO2021246757A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 | |
WO2022087156A1 (en) | Proinflammatory prodrugs | |
JP3266248B2 (ja) | 傷害を処置するための方法及び組成物 | |
US20230405118A1 (en) | Stat-activated macrophages, compositions, and uses thereof | |
AU2020338366B2 (en) | Phenothiazines and their derivatives for use as a medicament | |
WO2024147556A1 (ko) | K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물 | |
WO2023200069A1 (ko) | 에스트로겐과 항-pd-l1 항체를 포함하는 대장암 예방 또는 치료용 약학적 조성물 | |
WO2023095929A1 (ja) | 悪性腫瘍治療薬 | |
US20240058420A1 (en) | Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug | |
KR20050086819A (ko) | 알파 티모신을 사용한 방사능 손상에 대한 보호방법 | |
WO2024071464A1 (ko) | 말레이트 금속염을 포함하는 항암용 조성물 | |
WO2022235045A1 (ko) | Her2 백신 조성물 | |
Farman | Remodeling of Tumor Microenvironment for Enhanced Immunotherapy against Non-Melanoma Skin Cancer | |
WO2019208868A1 (ko) | 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21817193 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022574506 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021817193 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2021817193 Country of ref document: EP Effective date: 20230105 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |